191 related articles for article (PubMed ID: 18042685)
1. Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite.
Monteiro RQ; Rezaie AR; Bae JS; Calvo E; Andersen JF; Francischetti IM
Protein Sci; 2008 Jan; 17(1):146-53. PubMed ID: 18042685
[TBL] [Abstract][Full Text] [Related]
2. Ixolaris: a factor Xa heparin-binding exosite inhibitor.
Monteiro RQ; Rezaie AR; Ribeiro JM; Francischetti IM
Biochem J; 2005 May; 387(Pt 3):871-7. PubMed ID: 15617517
[TBL] [Abstract][Full Text] [Related]
3. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.
Francischetti IM; Valenzuela JG; Andersen JF; Mather TN; Ribeiro JM
Blood; 2002 May; 99(10):3602-12. PubMed ID: 11986214
[TBL] [Abstract][Full Text] [Related]
4. Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis.
Francischetti IM; Mather TN; Ribeiro JM
Thromb Haemost; 2004 May; 91(5):886-98. PubMed ID: 15116248
[TBL] [Abstract][Full Text] [Related]
5.
De Paula VS; Silva FHS; Francischetti IMB; Monteiro RQ; Valente AP
Biomol NMR Assign; 2017 Oct; 11(2):293-296. PubMed ID: 28856584
[TBL] [Abstract][Full Text] [Related]
6. NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition.
De Paula VS; Sgourakis NG; Francischetti IMB; Almeida FCL; Monteiro RQ; Valente AP
Blood; 2019 Aug; 134(8):699-708. PubMed ID: 31133602
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade.
Nazareth RA; Tomaz LS; Ortiz-Costa S; Atella GC; Ribeiro JM; Francischetti IM; Monteiro RQ
Thromb Haemost; 2006 Jul; 96(1):7-13. PubMed ID: 16807644
[TBL] [Abstract][Full Text] [Related]
8. Recombinant expression of Ixolaris, a Kunitz-type inhibitor from the tick salivary gland, for NMR studies.
De Paula VS; Silva FHS; Francischetti IMB; Monteiro RQ; Valente AP
Protein Expr Purif; 2017 Nov; 139():49-56. PubMed ID: 28734839
[TBL] [Abstract][Full Text] [Related]
9. Targeting exosites on blood coagulation proteases.
Monteiro RQ
An Acad Bras Cienc; 2005 Jun; 77(2):275-80. PubMed ID: 15895163
[TBL] [Abstract][Full Text] [Related]
10. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2.
Bergum PW; Cruikshank A; Maki SL; Kelly CR; Ruf W; Vlasuk GP
J Biol Chem; 2001 Mar; 276(13):10063-71. PubMed ID: 11139576
[TBL] [Abstract][Full Text] [Related]
11. The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions.
Bianchini EP; Pike RN; Le Bonniec BF
J Biol Chem; 2004 Jan; 279(5):3671-9. PubMed ID: 14583605
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
[TBL] [Abstract][Full Text] [Related]
13. Role of the Gla and first epidermal growth factor-like domains of factor X in the prothrombinase and tissue factor-factor VIIa complexes.
Thiec F; Cherel G; Christophe OD
J Biol Chem; 2003 Mar; 278(12):10393-9. PubMed ID: 12529356
[TBL] [Abstract][Full Text] [Related]
14. Directed glycosylation of human coagulation factor X at residue 333. Insight into factor Va-dependent prothrombin catalysis.
Cook BC; Rudolph AE; Kurumbail RG; Porche-Sorbet R; Miletich JP
J Biol Chem; 2000 Dec; 275(49):38774-9. PubMed ID: 10995746
[TBL] [Abstract][Full Text] [Related]
15. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation.
Baroni M; Pavani G; Pinotti M; Branchini A; Bernardi F; Camire RM
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1351-6. PubMed ID: 26012870
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex.
Takeyama M; Nogami K; Sasai K; Furukawa S; Shima M
Thromb Haemost; 2018 May; 118(5):830-841. PubMed ID: 29614522
[TBL] [Abstract][Full Text] [Related]
18. Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition.
Rezaie AR; Manithody C; Yang L
J Biol Chem; 2005 Sep; 280(38):32722-8. PubMed ID: 16079143
[TBL] [Abstract][Full Text] [Related]
19. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding.
Rezaie AR
J Biol Chem; 2000 Feb; 275(5):3320-7. PubMed ID: 10652320
[TBL] [Abstract][Full Text] [Related]
20. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor.
Zhong D; Bajaj MS; Schmidt AE; Bajaj SP
J Biol Chem; 2002 Feb; 277(5):3622-31. PubMed ID: 11723140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
